Senetek PLC Announces Debut Of Pyratine-6(TM) At The Annual Meeting Of The American Academy Of Dermatology

Senetek PLC (OTC
Bulletin Board: SNKTY), a Life Sciences company engaged in the development
of technologies that target the science of healthy aging, announced
the debut of Pyratine-6(TM) at the 66th Annual Meeting of the American
Academy of Dermatology in San Antonio, Texas.



Pyratine-6(TM), Senetek's exclusive second generation cytokinin, has
been clinically proven to be effective in correcting visible signs of skin
aging and significantly reducing erythema as early as two weeks from onset
of use.



The Annual Meeting of the American Academy of Dermatology runs from
February 1 - 5, 2008. Approximately 7,000 medical personnel are registered
to attend.



Commenting on the debut, Mr. Frank Massino, Senetek's Chairman and
Chief Executive Officer stated, "We are delighted to see this compelling
therapeutic come to the market and are very pleased by the reception
Pyratine-6(TM) has received from dermatologists at this important
conference. Pyratine-6(TM) has been successfully clinically tested and has
shown attributes more beneficial to treatment than any predecessor
compound."



About Senetek PLC



Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company
engaged in the development of breakthrough technologies that target the
science of healthy aging. The Company's extensive research collaborations
have resulted in a strong pipeline of patented compounds and products with
broad therapeutic applications and a leading presence in dermatology.
Senetek collaborates with established specialty pharmaceutical companies in
the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging
product sold in the North American physician market.



For more information, visit the company's website at
senetekplc.



This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such material
differences are described in the Company's Annual Report on Form 10-K for
the year 2006. However, the Company necessarily can give no assurance that
it has identified or will identify all of the factors that may result in
any particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.


Senetek PLC

senetekplc